Sampling times to capture second peak [Design Issues]

posted by Chiku – India, 2012-08-03 15:52 (5077 d 03:37 ago) – Posting: # 9031
Views: 3,770

In my opinion it is extremely vital to characterize the second peak especially for BE study with NCA of Pharmacokinetics.

we had a recent set back of MR product where double peaks were observed but due to non charecterization of second peak (less sampling time point) Cmax was bioequivalent ~90 % and AUC was no ~40 %.

there were other reasons as well but sampling time points was major reason.

I would say if second peak is due to formulation characteristics and it is variable i.e wide range of magnitude of second peak then for BE study it is vital atleast for AUC.
Although there can be number of categories the second peak can come such as multiple peak phenmenon due to physiological reason, MR formulation such as IR +DR, DR+ER, MMX etc. So careful evaluation of second peak is imp.

Regards
Chiku:)

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
369 visitors (0 registered, 369 guests [including 20 identified bots]).
Forum time: 19:29 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5